Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases

• US 10,383,868 B2
• Filed: 11/27/2016
• Issued: 08/20/2019
• Est. Priority Date: 11/28/2015
• Status: Active Grant

• Current Assignee: Neurodon Corp.
• Original Assignee: Russell Dahl
• Inventors: Dahl, Russell
• Primary Examiner(s): Baek, Bong-Sook
• Application Number:
  US15/361,485
• Publication Number:
  US 20170231973A1
• Time in Patent Office: 996 Days
• Field of Search: None
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings

Abstract

Provided herein are quinoline, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase.

Claims

1. A method for treating or ameliorating one or more symptoms of type 2 diabetes in a subject in need thereof, comprising administering to the subject an effective amount of a compound, wherein the compound is selected from the group consisting of:

2. The method of claim 1, wherein the method comprises administering to the subject a second therapeutic agent, in combination or alternation.

3. The method of claim 1, wherein the subject is a human.